What guidance did CareDx's management provide for the next earnings period?

What is CareDx's latest dividend and current dividend yield?

Did CareDx beat or miss consensus estimates last quarter?

What is the market's earnings forecast for CareDx next quarter?

What factors drove the changes in CareDx's revenue and profit?

What were the key takeaways from CareDx's earnings call?

What does CareDx do and what are its main business segments?

What is the revenue and EPS growth rate for CareDx year over year?

- **Revenue Momentum**: Q4 2025 revenue up 25% YoY to $108.4M, with Testing Services driving 23% growth. Full-year 2025 revenue $379.8M (+14% YoY). 
- **Strategic Product Launches**: AlloHeme (AML/MDS relapse detection) in pivotal trial, AlloSeq Tx11 (HLA typing) launched with IVDR certification. 
- **Operational Excellence**: RCM improvements reduce claim rejections by 60%, DSO from 71 to 41 days. 
- **2026 Outlook**: $420-444M revenue (+14% YoY midpoint), $30-45M EBITDA. Risks include $15M potential Medicare LCD impact. 
- **Growth Drivers**: Epic integrations, cell therapy pipeline, and 8-12% YoY Patient/Digital Solutions growth. 


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2025 revenue of $108.4M, up 25% YoY, driven by 17% testing volume growth. Full-year 2025 revenue $379.8M (+14% YoY). Testing Services revenue $274.5M (+10% YoY), with 200,000 tests (+14% YoY). 
- **Product Launches**: AlloSure Heart for Pediatrics, AlloSure Plus, HistoMap Kidney, and AlloSeq Tx11 launched to expand kidney, heart, and stem cell transplant solutions. 
- **Strategic Initiatives**: 
  - **Epic Integrations**: 7 centers live on Epic Aura, 14 in implementation, reducing login issues by 40% and improving workflow efficiency. 
  - **Cell Therapy Pipeline**: AlloHeme (AI-powered NGS surveillance for AML/MDS relapse) in pivotal trial with 85% sensitivity/92% specificity, targeting commercial launch in 2027. 
  - **RCM Improvements**: Claim rejection rates down 60% YoY, 0-pay claims reduced 10%, DSO improved from 71 to 41 days. 
- **Capital Allocation**: $88M share buybacks in 2025, no debt, $201.4M cash. 2026 guidance: $420-444M revenue (+14% YoY midpoint), $30-45M EBITDA. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Revenue: $108.4M (+25% YoY). Testing Services $78.4M (+23% YoY), Patient/Digital $16.8M (+47% YoY), Lab Products $13.3M (+17% YoY). 
  - Gross Margin: 68.5% (Q4) / 69.3% (FY25). 
  - EBITDA: $6.5M (Q4) / $31.7M (FY25). 
  - Cash Collections: $115.8M (Q4) / $405.6M (FY25). 
- **2026 Guidance**: 
  - Revenue: $420-444M (+14% YoY midpoint). Testing Services $306-326M, volumes 220-228K tests. 
  - EBITDA: $30-45M (+20% YoY midpoint). 
  - Impact of Medicare LCD: $15M annual revenue reduction if finalized. 
  - Operating Expenses: $68M/Q (+/- $1M), 63% of revenue. 

**【Q&A Highlights】**
- **Volume Growth**: 12% YoY testing volume guide reflects cautious assumptions on Epic Aura impact, with Q2 2026 clarity expected. 
- **Patient/Digital Solutions**: 8-12% YoY growth guided, with software margins 60-70%, product margins 50-60%. 
- **LCD Impact**: $7.5M 2026 EBITDA reduction from potential HeartCare coverage restriction. 
- **Epic Integration ROI**: $10M investment in Epic Enterprise LIMS for 3-year 2,000-test target, offsetting $5M+ in denied claims. 
- **AlloHeme Commercialization**: CLIA readiness in 2026, 2028 payer coverage, targeting cell therapy market. 
- **Capital Allocation**: Core growth prioritized over M&A, with share buybacks contingent on valuation. 


CareDx, Inc(CDNA)-20260225-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 revenue up 21% YoY to $100.1M, with Testing Services leading at +19%.
- **New Product Momentum**: HistoMap Kidney (Q2 2026 launch) and AlloSeq Tx11 enhance diagnostic offerings.
- **Operational Excellence**: 20% order turnaround time reduction via EPIC, 124% cash collections vs. Testing Services revenue.
- **Guidance Raise**: 2025 revenue updated to $372M-$376M, EBITDA to $35M-$39M, reflecting strong RCM performance.

**【CEO Summary Section】**
- **Record Q3 Performance**: Total revenue of $100.1 million, up 21% YoY, driven by Testing Services ($72.2M, +19%), Patient & Digital Solutions ($15.4M, +30%), and Lab Products ($12.5M, +22%).
- **New Product Launches**: HistoMap Kidney (commercial launch Q2 2026) and AlloSeq Tx11 (enhanced HLA typing solution) announced at medical conferences.
- **Strategic Hires**: Appointment of Dr. Jeff Teuteberg as CMO and Suresh Gunasekaran to the Board, strengthening clinical and customer insights.
- **Operational Wins**: 20% reduction in order turnaround time via EPIC integration and 124% cash collections vs. Testing Services revenue.
- **Guidance Update**: Full-year 2025 revenue raised to $372M-$376M, EBITDA to $35M-$39M.

**【CFO Financial Commentary】**
- **Financial Highlights**: Non-GAAP gross margin 70.9%, operating expenses down 5% YoY to 58% of revenue. Adjusted EBITDA $15.3M (+108% YoY).
- **Cash Flow Strength**: $119M cash collections (including $5.9M prior-period claims), ending Q3 with $194.2M cash.
- **Q4 Outlook**: Revenue $101M-$105M, ASP $1,400-$1,420 (inclusive of $4M-$6M collections benefit).

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: 14% YoY adjusted revenue driven by Testing Services expansion and AI-driven product launches (AlloSure Plus, pediatric AlloSure Heart).
- **LCD Policy Risk**: Potential $15M-$30M headwind from Draft LCD scenarios, with focus on maintaining protocol adherence and evidence generation.
- **Operational Efficiency**: 60% reduction in claim submission time, 45% increase in prior auth success, and 105% cash collections of Testing Services revenue.
- **CFO Transition**: Abhishek Jain retiring; industry veteran Nathan Smith appointed CFO to support growth strategy.

**【CEO Summary Section】**
- **Revenue Growth**: Adjusted revenue reached $90.5 million, up 14% YoY, driven by Testing Services growth of 14% and 13% sequential testing volume growth across all organ types.
- **Product Launches**: Introduced AlloSure Plus, an AI-driven diagnostic for kidney transplant monitoring, and expanded AlloSure Heart for pediatric patients. Over 40 abstracts and 16 oral presentations at WTC highlighted clinical utility of AlloSure and HeartCare.
- **LCD Policy Impact**: Modeled two scenarios for the Draft LCD policy: $15M headwind (bundled payments) and $30M headwind (no AlloMap Heart reimbursement). Continued focus on protocol adherence despite policy uncertainty.
- **Operational Excellence**: Reduced claim submission time by 60%, increased prior auth success rate by 45%, and achieved 105% cash collections of Testing Services revenue.
- **Guidance Update**: Narrowed 2025 revenue range to $367M-$373M, reaffirming adjusted EBITDA of $29M-$33M.

**【CFO Financial Commentary】**
- **Financial Results**: GAAP revenue $86.7M (down 6% YoY) due to $3.8M prior-period test write-off. Adjusted Testing Services revenue $65.9M (up 14% YoY). Non-GAAP gross margin improved 340bps to 70.4%, driven by lab efficiency and pricing.
- **Cash Flow**: Generated $10M in operating cash flow, ending Q2 with $186M in cash after $50M share repurchase.
- **Guidance**: Full-year ASP ~$1,360/test, 70% gross margin, and $235M operating expenses. Patient & Digital Solutions expected to grow low-20s, Lab Products mid-teens.

**【Q&A Key Highlights】**
- **LCD Policy Discussion**: Focused on frequency limits, multimodal testing evidence, and bundled payments in public comments. No LRP updates until policy clarity.
- **Organ Growth**: Heart and Lung testing volumes grew steadily, with Lung showing steady progress despite smaller share. ISHLT event temporarily impacted heart volumes.
- **EPIC Rollout**: 3 pilot sites launching Q3, aiming for 10% volume by year-end and 50% adherence by end-2026. Challenges include integration complexity.
- **CFO Transition**: Abhishek Jain retiring, Nathan Smith (Myriad Genetics veteran) joining as CFO effective August 7.

CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 18% YoY to $84.7M, driven by 12% test volume growth and 24% patient/digital solutions expansion.
- **New Indications Target 1,200+ Procedures**: Expanded AlloSure to pediatric heart transplants (<7 years) and simultaneous pancreas-kidney transplants.
- **Epic Integration to Boost Efficiency**: Streamlined test ordering via Epic Aura, reducing prior auth friction and improving ASP collection.
- **Gross Margin Expansion**: 68.5% non-GAAP gross margin (+150bps YoY), fueled by ASP growth and cost optimization.
- **Litigation Resolution**: $20.25M class action settlement (company OPEX: $5.4M), clearing legal uncertainty.

**【CEO Summary Section】**
- Q1 2025 revenue reached $84.7 million, up 18% YoY, driven by 12% growth in testing volumes (47,100 tests) and 24% expansion in patient/digital solutions revenue.
- Launched expanded indications for AlloSure Heart (pediatric <7 years) and AlloSure Kidney (simultaneous pancreas-kidney transplants), targeting ~1,200 annual procedures.
- Announced Epic Aura integration to streamline test ordering, aiming for full deployment by Q4 2025.
- Reiterated 2025 guidance: $365-375M revenue, $29-33M adj. EBITDA, and $500M/20% adj. EBITDA by 2027.

**【CFO Financial Commentary】**
- Non-GAAP gross margin improved 150bps YoY to 68.5%, driven by ASP expansion (+$110/test YoY) and cost efficiency.
- Operating expenses grew 6% YoY to $55.5M, with 35-40% reduction in stock-based compensation expected in 2025.
- Ended Q1 with $231M cash, up $15M YoY, and no debt.
- Settle securities class action for $20.25M (company OPEX: $5.4M), resolving litigation risk.

**【Q&A Highlights】**
- **Surveillance Volume Recovery**: 500-600 tests impacted by weather, but Q2 growth on track with protocol reactivation.
- **Epic Integration Costs**: ~$5M annual investment, but expects long-term ASP uplift via cleaner claims processing.
- **MAC LCD Timing**: No update on potential kidney surveillance coverage expansion.
- **Competitive Landscape**: Unconcerned by OncoCyte's long-term development timeline.
- **2025 Outlook**: 17% revenue growth (mid-teens testing volumes, mid-teens non-testing growth), 70% gross margin, $235M opex.

CareDx (CDNA)-30 Apr 25-2025 Q1 Earnings call transcript

- **Record Growth**: FY24 revenue up 19% to $334 million, Q4 revenue up 32% to $86.6 million. 
- **Profitability Expansion**: Adjusted EBITDA turned positive ($27.8M FY24 vs -$38M FY23), cash balance $261M. 
- **Pipeline Momentum**: 2025 launches include 4 new AlloSure tests, XynQAPI IOTA compliance tool, and CareDx MTM program. 
- **Gross Margin Improvement**: Testing Services gross margin up 500bps to 78.9%, full year gross margin 69.4%. 
- **Strategic Focus**: IOTA program compliance, xenotransplantation partnerships, and $50M buyback authorization.

**【CEO Summary Section】**
- Q4 2024 revenue: $86.6 million (32% YoY growth), full year 2024 revenue: $334 million (19% YoY growth). 
- Adjusted EBITDA: $9.8 million (Q4) / $27.8 million (FY24), cash balance: $261 million (no debt). 
- Key growth drivers: Testing Services (+37% YoY), Patient/Digital Solutions (+18% YoY), Lab Products (+23% YoY). 
- 2025 guidance: $365-375 million revenue, 17% growth midpoint. 
- New product launches: AlloSure Heart Peds, AlloSure Simultaneous Pancreas/Kidney, HistoMap Kidney. 
- Strategic initiatives: IOTA program compliance tools, transplant pharmacy MTM program, OPTN modernization partnership. 

**【CFO Financial Commentary】**
- Full year 2024 non-GAAP gross margin: 69.4% (vs 66.6% FY23). 
- Testing Services gross margin: 78.9% (vs 74% FY23), driven by volume growth and ASP expansion. 
- Operating expenses: $212 million (FY24) vs $233 million FY23, down 9% due to legal savings. 
- 2025 guidance: Non-GAAP gross margin ~70%, operating expenses ~$235 million (+11% YoY). 
- Q1 2025 EBITDA: ~$3 million (low single-digit), ramping to $33 million annual target. 

**【Q&A Highlights】**
- **Litigation Update**: $96 million patent litigation accrual reversed, case likely to be appealed. 
- **Capital Allocation**: $50M share buyback authorized, prioritizing organic growth & strategic M&A. 
- **ASP Strategy**: New billing team to improve collections, 2025 ASP target $1,360/test. 
- **Clinical Trials**: AlloHeme ACROBAT trial interim data shows early rejection detection, full results expected 2026. 
- **Xenotransplantation**: Active partnerships with all major xeno transplant programs. 

**【Operational Excellence】**
- 650+ employees supporting 50,000+ patients annually. 
- Testing volumes: 176,000 FY24 (6% YoY growth), 45,500 Q4 (14% YoY). 
- Lab product gross margin improvement initiatives underway. 
- 2027 target: $500 million revenue, 20% adjusted EBITDA margin.

Actual												-0.14	-0.15	-0.06	-0.07	-0.01	-0.04	-0.23	-0.31	-0.37	-0.41	-0.32	-0.34	-0.44	-0.46	-0.43	-2.21	-0.32	-0.03	-0.14	1.51	-0.19	-0.16	0.03	-0.08
Forecast												-0.1325	-0.15	-0.196	-0.1378	-0.118	-0.086	-0.1375	-0.138	-0.275	-0.34	-0.392	-0.3338	-0.3228	-0.5446	-0.5883	-0.4467	-0.4735	-0.3989	-0.2462	-0.4082	-0.2067	-0.0964	-0.0819	0.0199
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.66%	0.00%	+69.39%	+49.20%	+91.53%	+53.49%	-67.27%	-124.64%	-34.55%	-20.59%	+18.37%	-1.86%	-36.31%	+15.53%	+26.91%	-394.74%	+32.42%	+92.48%	+43.14%	+469.92%	+8.08%	-65.98%	+136.63%	-502.01%

CDNA

CDNA fundamentals

CDNA Q4 2025 Earnings

Earnings Call

You can ask Aime

CDNA

CDNA fundamentals

CDNA Q4 2025 Earnings

Earnings Call

CDNA Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

CDNA Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

CDNA Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

CDNA Earnings Call Summary for Q1/20254:30 PM on Apr 30, 2025

CDNA Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime